WGS Share Price Performance
US$135.94
59.01 (76.71%)
13.4% undervalued intrinsic discount
US$156.97
Fair Value
Price US$135.94
AnalystHighTarget US$156.97
AnalystConsensusTarget US$164.78
AnalystLowTarget US$95.00
Fair ValueUS$156.97
Share Pricen/a
GeneDx Holdings Corp. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 42 Fair Values set on narratives written by author
WGS Community Narratives
AN
Fair Value US$156.97 13.4% undervalued intrinsic discount
Genomics And AI Integration Will Expand Precision Healthcare Adoption
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$164.78 17.5% undervalued intrinsic discount
WGS: Customer Conversion And Market Expansion Will Shape Rare Disease Diagnostics
0users have liked this narrative
0users have commented on this narrative
22users have followed this narrative
AN
Fair Value US$95 43.1% overvalued intrinsic discount
Government Cost-Containment And Tightening Privacy Laws Will Squeeze Margins
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
WGS: Customer Conversion And Market Expansion Will Shape Rare Disease Diagnostics
Key Takeaways Accelerating adoption of genomics in pediatrics and enhanced AI platforms drive growth, efficiency, and margin improvement while reinforcing competitive advantage. Increasing reimbursement, enriched rare disease datasets, and global biopharma partnerships support recurring revenues, premium pricing, and high barriers to entry.Read more
171
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
22users have followed this narrative
AN
US$164.78
17.5% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
21.71% p.a.
Profit Margin
5.78%
Future PE
149.23x
Price in 2028
US$198
Genomics And AI Integration Will Expand Precision Healthcare Adoption
Key Takeaways Exclusive data, AI platform, and strategic integration efforts position GeneDx for sustained market leadership, margin expansion, and outperformance relative to analyst expectations. Shifts in testing guidelines and biopharma partnerships will catalyze broad adoption, recurring high-margin revenues, and accelerating competitive advantage through network effects.Read more
16
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$156.97
13.4% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
23.89% p.a.
Profit Margin
18.84%
Future PE
47.11x
Price in 2028
US$186.17
Government Cost-Containment And Tightening Privacy Laws Will Squeeze Margins
Key Takeaways Rising regulatory and reimbursement pressures threaten to squeeze margins and limit GeneDx's ability to capitalize on its genomic database. Intensifying industry competition and slow clinical adoption risk eroding market share and dampening growth prospects.Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$95
43.1% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
19.57% p.a.
Profit Margin
15.67%
Future PE
38.12x
Price in 2028
US$112.67
Trending Discussion
Recently Updated Narratives
AN
WGS: Newborn Genomic Screening Partnerships Will Support Balanced Long-Term Opportunity
Fair Value: US$164.78 17.5% undervalued intrinsic discount
22 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Government Cost-Containment And Tightening Privacy Laws Will Squeeze Margins
Fair Value: US$95 43.1% overvalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Genomics And AI Integration Will Expand Precision Healthcare Adoption
Fair Value: US$156.97 13.4% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
GeneDx Holdings Corp. Key Details
About WGS
- Founded
- n/a
- Employees
- 1000
- CEO
- WebsiteView website
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The company is headquartered in Stamford, Connecticut.
